Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 82
Selected: 0
NCT IDTitle
NCT05318820A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT02590965A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT02133157Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT03860948A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
NCT03627520A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT03778229Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03483948Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT04272957A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT02601248Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT05029635Phase III Study on HMPL-523 for Treatment of ITP
NCT05842525Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT03684967Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT05190068HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT01955304Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT04716634Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
NCT04577963A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT03951623The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT02267967Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
NCT02017236A Food Effect Phase I Study of the Volitinib in Healthy Subjects
NCT02601274Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02252913A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
NCT05009836Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT02314819A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT04755075Surufatinib Hepatic Impairment Study
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT05509699Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
NCT05173142HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
NCT02415023A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT01882764HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
NCT03977090Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
NCT05522738Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT01985555Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT02966821Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed